BioCentury | Apr 11, 2011
Finance

Playing tax arbitrage

...also shelter income from marketed Cephalon products either through its existing Swiss presence or through Mepha AG...
BioCentury | Feb 14, 2011
Finance

Next phase for Phase4

...to $101.6M from $34.2M. The company attributed the rise to the acquisition of generics company Mepha AG...
BioCentury | Jan 10, 2011
Strategy

A Remembrance: Force of Nature

...The pace did not slow in his last year, with the acquisitions of generics company Mepha AG...
...was. I had a quiet moment with his management team and complimented them on the Mepha...
BioCentury | Apr 19, 2010
Company News

Cephalon, Mepha deal

...its previously announced acquisition of generics company Mepha for CHF662.4 million ($623.4 million) in cash. Mepha...
...a wholly owned subsidiary of Cephalon (see BioCentury, Feb. 8). Cephalon Inc. (NASDAQ:CEPH), Frazer, Pa. Mepha AG...
BioCentury | Feb 12, 2010
Financial News

Cephalon beats Street

...billion and EPS of $6.80-$7. The 2010 estimates assume that the acquisition of generics company Mepha AG...
BioCentury | Feb 8, 2010
Finance

Regulatory milestones

...NASDAQ:CEPH) was up $0.64 to $64.48 last week after saying it will acquire generics company Mepha AG...
BioCentury | Feb 8, 2010
Strategy

Footprint for growth

...Cephalon Inc. Chairman and CEO Frank Baldino says the company's proposed acquisition of generics company Mepha AG...
...the years, and our European business, which included branded generics, helped to drive that growth. Mepha...
...added. Last week, Cephalon proposed to acquire Mepha for CHF622.5 million ($587.9 million) in cash. Mepha's...
BioCentury | Feb 8, 2010
Company News

Cephalon, Mepha AG deal

...Cephalon announced on Feb. 1 that it will acquire generics company Mepha for CHF622.5 million ($587.9...
...size of its international presence, expanding its reach in Europe, Africa and the Middle East. Mepha...
...which is expected to close in the next 10-12 weeks. Cephalon Inc. (NASDAQ:CEPH), Frazer, Pa. Mepha AG...
BioCentury | Feb 2, 2010
Top Story

Cephalon to acquire Mepha

...Cephalon Inc. (NASDAQ:CEPH) will acquire generics company Mepha AG (Basel, Switzerland) for CHF622.5 million ($587.9 million) in...
...size of its international business, expanding its reach in Europe, Africa and the Middle East. Mepha...
BioCentury | Sep 25, 2000
Company News

Cephalon sales and marketing update

...oral alpha adrenergic stimulant to treat narcolepsy. CEPH licensed Swiss rights to the compound from Mepha...
Items per page:
1 - 10 of 10
BioCentury | Apr 11, 2011
Finance

Playing tax arbitrage

...also shelter income from marketed Cephalon products either through its existing Swiss presence or through Mepha AG...
BioCentury | Feb 14, 2011
Finance

Next phase for Phase4

...to $101.6M from $34.2M. The company attributed the rise to the acquisition of generics company Mepha AG...
BioCentury | Jan 10, 2011
Strategy

A Remembrance: Force of Nature

...The pace did not slow in his last year, with the acquisitions of generics company Mepha AG...
...was. I had a quiet moment with his management team and complimented them on the Mepha...
BioCentury | Apr 19, 2010
Company News

Cephalon, Mepha deal

...its previously announced acquisition of generics company Mepha for CHF662.4 million ($623.4 million) in cash. Mepha...
...a wholly owned subsidiary of Cephalon (see BioCentury, Feb. 8). Cephalon Inc. (NASDAQ:CEPH), Frazer, Pa. Mepha AG...
BioCentury | Feb 12, 2010
Financial News

Cephalon beats Street

...billion and EPS of $6.80-$7. The 2010 estimates assume that the acquisition of generics company Mepha AG...
BioCentury | Feb 8, 2010
Finance

Regulatory milestones

...NASDAQ:CEPH) was up $0.64 to $64.48 last week after saying it will acquire generics company Mepha AG...
BioCentury | Feb 8, 2010
Strategy

Footprint for growth

...Cephalon Inc. Chairman and CEO Frank Baldino says the company's proposed acquisition of generics company Mepha AG...
...the years, and our European business, which included branded generics, helped to drive that growth. Mepha...
...added. Last week, Cephalon proposed to acquire Mepha for CHF622.5 million ($587.9 million) in cash. Mepha's...
BioCentury | Feb 8, 2010
Company News

Cephalon, Mepha AG deal

...Cephalon announced on Feb. 1 that it will acquire generics company Mepha for CHF622.5 million ($587.9...
...size of its international presence, expanding its reach in Europe, Africa and the Middle East. Mepha...
...which is expected to close in the next 10-12 weeks. Cephalon Inc. (NASDAQ:CEPH), Frazer, Pa. Mepha AG...
BioCentury | Feb 2, 2010
Top Story

Cephalon to acquire Mepha

...Cephalon Inc. (NASDAQ:CEPH) will acquire generics company Mepha AG (Basel, Switzerland) for CHF622.5 million ($587.9 million) in...
...size of its international business, expanding its reach in Europe, Africa and the Middle East. Mepha...
BioCentury | Sep 25, 2000
Company News

Cephalon sales and marketing update

...oral alpha adrenergic stimulant to treat narcolepsy. CEPH licensed Swiss rights to the compound from Mepha...
Items per page:
1 - 10 of 10